Why might ubrelvy (ubrogepant) fail to relieve a migraine?

Why Ubrelvy (Ubrogepant) May Not Work for Migraine

Ubrelvy may fail to relieve migraine because it is inherently less effective than first-line combination therapy (triptan + NSAID), with only 1 in 5 patients achieving complete pain freedom, and its efficacy is further reduced in patients with chronic migraine, multiple prior treatment failures, or those who have not first tried recommended first-line therapies.

Evidence-Based Reasons for Treatment Failure

1. Lower Intrinsic Efficacy Compared to Recommended First-Line Therapy

The most recent 2025 American College of Physicians guideline explicitly positions ubrogepant as a second-line option after combination therapy fails 1. The evidence shows:

• CGRP antagonists-gepants (including ubrogepant) have lower likelihood of pain freedom and relief at 2 hours compared to triptan + NSAID combination therapy (low-certainty evidence) 1
• Real-world data demonstrates only 19% of patients achieve complete headache freedom (from any pain level to no pain) at 2 hours 2
• The Number Needed to Treat (NNT) for ubrogepant is 12, which is comparable to acetaminophen alone and significantly worse than triptans 3

2. Patient Was Not Optimized on First-Line Therapy First

The most common reason ubrelvy fails is premature use before exhausting recommended first-line options 1:

The 2025 ACP guideline provides a clear treatment algorithm:

• Step 1: Ensure adequate dosing of NSAID or acetaminophen
• Step 2: Add a triptan to NSAID (or acetaminophen if NSAIDs contraindicated)
• Step 3: Only after inadequate response or intolerance to combination therapy, consider gepants like ubrogepant 1

If ubrelvy was prescribed without first optimizing combination therapy, treatment failure is predictable based on comparative effectiveness data.

3. Chronic Migraine and Treatment-Refractory Disease

Real-world evidence identifies specific predictors of ubrogepant failure 2:

Poor responders (defined as <75% headache relief at 2 hours) are more likely to have:

• Chronic migraine (86.8% of real-world patients had chronic migraine, with lower response rates)
• ≥5 prior unsuccessful preventive or acute treatment trials
• Migraine without aura (migraine with aura predicted better response)
• Episodic migraine patients respond better than chronic migraine patients 2

4. Timing of Administration

The 2025 ACP guideline emphasizes that patients should "begin treatment of migraine headache as soon as possible after its onset" 1. Delayed administration reduces efficacy for all acute migraine treatments, including ubrogepant.

5. Drug Interactions Reducing Efficacy

Strong CYP3A4 inducers (phenytoin, barbiturates, rifampin, St. John's Wort) significantly reduce ubrogepant exposure and should be avoided 4. If a patient is taking these medications, ubrelvy will have reduced or absent efficacy.

6. Wrong Diagnosis or Migraine Subtype

Ubrogepant is only indicated for acute treatment of migraine with or without aura 4. It is:

• NOT indicated for migraine prevention 4
• Not studied in mild migraine (only moderate to severe) 1
• May not work if the headache is not actually migraine (tension-type headache, medication overuse headache, etc.)

7. Medication Overuse Headache

If the patient is using acute migraine medications ≥10 days per month (for triptans/gepants) or ≥15 days per month (for NSAIDs), they may have developed medication overuse headache, which makes all acute treatments less effective 1.

Clinical Algorithm for Addressing Ubrelvy Failure

When ubrelvy doesn't work, systematically evaluate:

1. Has the patient tried adequate first-line therapy?

   • Adequate dose NSAID (e.g., naproxen 500-825mg) or acetaminophen 1000mg?
   • If yes, have they tried triptan + NSAID combination? 1
   • If no to either, optimize first-line therapy before continuing ubrelvy

2. Is this chronic migraine (≥15 headache days/month)?

   • If yes, preventive therapy is warranted, not just acute treatment 1
   • Consider CGRP monoclonal antibodies, topiramate, or other preventives

3. Check for drug interactions:

   • Strong CYP3A4 inducers? (phenytoin, barbiturates, rifampin, St. John's Wort) 4
   • If yes, discontinue inducer or switch to alternative acute treatment

4. Assess for medication overuse headache:

   • Using acute medications ≥10 days/month (triptans/gepants) or ≥15 days/month (NSAIDs)? 1
   • If yes, initiate medication withdrawal protocol and preventive therapy

5. Timing and dosing optimization:

   • Is patient taking ubrelvy early in attack? 1
   • Did they try a second dose 2 hours later (if no drug interactions)? 4

6. Consider alternative gepant or treatment class:

   • Different patients respond to different medications within the same class 1
   • However, if ubrogepant failed and first-line therapy was optimized, consider lasmiditan (ditan class) as the next option 1

Important Caveats

• Prior response to CGRP monoclonal antibodies predicts ubrogepant response: Patients who respond well to preventive CGRP antibodies are more likely to respond to ubrogepant 2
• Ubrogepant efficacy does NOT depend on prior triptan response: Post-hoc analysis showed ubrogepant works equally in triptan responders, triptan-insufficient responders, and triptan-naïve patients 5
• Adverse events are more common in real-world use (39.6%) than in clinical trials, particularly fatigue (27.4%) 2, which may lead to perceived "failure" even if headache improves

The bottom line: Ubrelvy's modest efficacy (NNT=12) means it will fail in many patients, particularly those with chronic migraine or multiple prior treatment failures. It should only be used after optimizing first-line combination therapy (triptan + NSAID), and failure should prompt reassessment of diagnosis, preventive therapy needs, and medication overuse.